Unpacking Key Data in Chronic Myeloid Leukemia After ASH 2024 - Episode 4

Emerging Mutation Analysis from the OPTIC Trial

,

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the mutational analysis for ponatinib in the OPTIC trial in CP-CML.

EP. 1: Implications of the FDA Approval of Asciminib for Newly Diagnosed, Ph+ CP-CML
EP. 2: Factors That Influence Treatment Decisions in Later-Line CML
EP. 3: 5-year Data for Ponatinib in Pretreated CP-CML from the OPTIC Trial
Now Viewing
EP. 4: Emerging Mutation Analysis from the OPTIC Trial
EP. 5: Dosing Strategies for Ponatinib in CML and ALL
EP. 6: The Role of Frontline Ponatinib Plus Chemo in Ph+ ALL
EP. 7: Selecting a TKI in Subsequent Lines of Therapy in CML
EP. 8: Highlighting Key CML/ALL Data Presented at ASH 2024

Related Content:

Unpacking Key Data in Chronic Myeloid Leukemia After ASH 2024Mayo ClinicMoffitt Cancer CenterOncLive News Network®Hematologic Oncology
Maintenance Galinpepimut-S Appears Effective and Safe in AML in Second CR
Highlighting Key CML/ALL Data Presented at ASH 2024
Selecting a TKI in Subsequent Lines of Therapy in CML